BYSI - BeyondSpring Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
26.89
+0.58 (+2.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close26.31
Open26.70
Bid26.00 x 1000
Ask27.80 x 800
Day's Range26.55 - 27.09
52 Week Range19.55 - 48.49
Volume6,393
Avg. Volume12,654
Market Cap623.17M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-4.40
Earnings DateJun 21, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est55.38
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    BeyondSpring to Host First-Quarter 2018 Financial Results Conference Call on June 21, 2018

    NEW YORK, June 18, 2018-- BeyondSpring Inc., a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will report ...

  • GlobeNewswire20 days ago

    BeyondSpring to Present at Upcoming Conferences

    BeyondSpring is a global, clinical-stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN).

  • GlobeNewswire21 days ago

    BeyondSpring Announces $20 Million Registered Direct Offering

    BeyondSpring Inc. (BYSI) (“BeyondSpring”), a global, clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cancer therapies, today announced that it has raised aggregate gross proceeds of $20 million through a registered direct offering of its ordinary shares to certain strategic investors (the “Investors”). On May 29, 2018, BeyondSpring entered into a series of securities purchase agreements (collectively, the “Purchase Agreements”) with the Investors pursuant to which the Company agreed to issue and sell, in a registered offering by the Company, an aggregate of 739,095 shares of the Company’s ordinary shares, par value $0.0001 per share (the “Shares”), at a purchase price of $27.06 per share, for aggregate gross proceeds of $20 million, before deducting offering expenses.

  • GlobeNewswirelast month

    BeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the Prevention of Chemotherapy-Induced Neutropenia at 2018 ASCO Annual Meeting

    BeyondSpring Inc. (BYSI), a global clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will present results of the Phase 2 portion of Study 105, a prospective Phase 2/3 trial of its lead asset, Plinabulin, during a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 4, 2018. Importantly, data from the study demonstrated that patients treated with Plinabulin dosed 30 minutes after docetaxel for the prevention of docetaxel chemotherapy-induced neutropenia (CIN) reported less bone pain, which was clinically meaningful, and had superior neutrophil counts and comparable neutropenia reduction compared to patients treated with Neulasta® (pegfilgrastim) 24 hours after docetaxel.

  • BeyondSpring Inc. (BYSI) Sees Hammer Chart Pattern: Time to Buy?
    Zackslast month

    BeyondSpring Inc. (BYSI) Sees Hammer Chart Pattern: Time to Buy?

    BeyondSpring Inc. (BYSI) Sees Hammer Chart Pattern: Time to Buy?

  • GlobeNewswirelast month

    BeyondSpring to Present at the Deutsche Bank 43rd Annual Health Care Conference

    NEW YORK, May 07, 2018-- BeyondSpring Inc., a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that Lan Huang, Ph.D., Chairman, ...

  • GlobeNewswire2 months ago

    BeyondSpring to Present Neutropenia Clinical Trial Data on Lead Asset, Plinabulin, at 2018 ASCO Annual Meeting

    NEW YORK, April 25, 2018-- BeyondSpring Inc., a global clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will present ...

  • TheStreet.com2 months ago

    BeyondSpring CEO Reveals Novel Tumor Therapy

    New York-based BeyondSpring develops oncology products with Plinabulin, a small molecule that attacks tumors and can activate the Rho guanine nucleotide exchange factor GEF-H1, which could play a role in managing a variety of diseases. Research has confirmed "the roles of GEF-H1 in epithelial barrier permeability, cell motility and polarization, dendritic spine morphology, antigen presentation, leukemic cell differentiation, cell cycle regulation, and cancer," according to the National Health Institutes' NCBI. "GEF-H1 might also contribute to pathophysiological signaling involved in leukemias, and in cancers associated with mutated p53 tumor suppressor gene, epithelial and endothelial cell dysfunction, infectious disease, and cardiac hypertrophy.

  • GlobeNewswire2 months ago

    BeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced Neutropenia

    NEW YORK, April 17, 2018-- BeyondSpring Inc., a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced the presentation of preclinical ...

  • Why BeyondSpring (BYSI) Could Be a Potential Winner
    Zacks2 months ago

    Why BeyondSpring (BYSI) Could Be a Potential Winner

    Although overlooked by the investors, BeyondSpring (BYSI) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.

  • GlobeNewswire3 months ago

    BeyondSpring Files Its 2017 Annual Report on Form 20-F

    NEW YORK, April 03, 2018-- BeyondSpring Inc., a global clinical stage biopharmaceutical company focusing on the development of innovative cancer therapies, today announced that the Company has filed its ...

  • GlobeNewswire3 months ago

    BeyondSpring Provides Operational Update and Fourth-Quarter and Full-Year 2017 Financial Results

    NEW YORK, April 03, 2018-- BeyondSpring Inc., a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced its fourth-quarter and full-year ...

  • GlobeNewswire3 months ago

    BeyondSpring to Host Fourth-Quarter and Full-Year 2017 Financial Results Conference Call on April 3, 2018

    NEW YORK, March 27, 2018-- BeyondSpring Inc., a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will report ...

  • GlobeNewswire3 months ago

    BeyondSpring Appoints Edward Dongheng Liu as Chief Financial Officer

    NEW YORK, March 27, 2018-- BeyondSpring Inc., a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, announced today the appointment of Edward ...